Dose Insider / FDA warning letters / Xcel Research LLC

Xcel Research LLCFDA warning letter, December 10, 2024

FDA letter of December 10, 2024 · posted December 17, 2024 · checked against fda.gov on November 20, 2026

On December 10, 2024, FDA sent Xcel Research LLC of Sheridan, WY, a warning letter saying that xcelpeptides.com offered semaglutide, retatrutide, cagrilintide, survodutide and mazdutide that FDA considers unapproved new drugs.

2 sectionsof the Food, Drug, and Cosmetic Act cited in the letter
FDA letters on GLP-1 drugs, by yearAll 164 letters in this database; the year of this one in coral202322024, this letter11202573202678FDA letters on GLP-1 drugs,by yearAll 164 letters in this database; the year of thisone in coral202322024, this letter11202573202678

16 letters are of the same kind as this one: other matters, such as a clinical investigator or a supplement.

On this page

The letter notes that products were labeled for research use only or not for human consumption.

FDA posted the letter on December 17, 2024. As of November 20, 2026, FDA’s database lists no close-out letter for it. It is one of 164 FDA warning letters about GLP-1 drugs in this database, which we built from FDA’s own records.1

What does the letter say, in brief?

CompanyXcel Research LLC
LocationSheridan, WY
Website namedxcelpeptides.com
Letter datedDecember 10, 2024
Posted by FDADecember 17, 2024
Issuing officeCenter for Drug Evaluation and Research (CDER)
FDA’s subject lineUnapproved New Drugs/Misbranded
Drugs namedsemaglutide, retatrutide, cagrilintide, survodutide and mazdutide
Kind of letterOther
Reply asked withinfifteen working days
Close-out letterNone posted as of November 20, 2026
FDA recordMARCS-CMS 694608

What did FDA quote?

The letter quotes 12 passages. FDA quotes them as examples and says in most letters that the list is not exhaustive.1

4 more quotes are in the full letter below.

Which parts of the law did FDA cite?

The letter cites 2 sections of the Federal Food, Drug, and Cosmetic Act. The right-hand column shows how many of the 164 letters in this database cite the same section.

SectionWhat it saysLetters citing it
505(a)A new drug may not be sold across state lines without an approved application48
301(d)It is prohibited to introduce a drug into interstate commerce in violation of section 50548

What did FDA ask the company to do?

In the letter’s own words:

FDA has not posted a reply or a close-out letter for this case. A reply sent to FDA is not always published.1

Has FDA warned the seller I use?

Type a seller’s name or website. The search runs over all 164 letters in this database.

Seller check164 letters
Letters found—
Latest—

How many GLP-1 letters has FDA sent?

16 letters in this database are of the same kind as this one, other matters, such as a clinical investigator or a supplement. 151 of the 164 letters name semaglutide. 21 of the 164 letters name retatrutide. 5 of the 164 letters name cagrilintide. 2 of the 164 letters name survodutide. 4 of the 164 letters name mazdutide. The chart counts letters by the quarter of their date; the quarter of this letter is marked.

Letters by quarter2023–2026
Drug named in the letter
Kind of letter
Letters—
Busiest quarter—

Which other sellers got a similar letter?

What does an FDA warning letter mean for someone buying from this seller?

FDA sends a warning letter when it finds what it believes are significant violations of federal law. The letter names the concerns, such as how a drug was made or what a seller claimed about it, and asks for a reply within a set time.2 A letter is not a court ruling and not a recall. The company can correct the problems or send FDA its reasons for disagreeing.

FDA itself warns that what happened after a letter may have changed the regulatory status of the issues in it.3 When the issuing office has checked that the corrections are adequate, it can issue a close-out letter; if the violations are seen again, FDA can take enforcement action without further notice.2 So the date matters: a letter from 2024 says what FDA found then, not what the seller does today.

A seller with no letter is not a seller FDA has approved. FDA does not approve compounded drugs or the websites that sell them, and most sellers have never been reviewed in a letter at all.

What is the full text of the letter?

This is the letter as FDA published it on fda.gov, without the page navigation. Letters from the U.S. government are in the public domain.1

Read the full letter (1387 words)

December 10, 2024

RE: 694608

Dear Andrew Pierce:

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https://www.xcelpeptides.com in October 2024 and has observed that your website offers various products such as “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN,” for sale in the United States. As described below, your “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN,” products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).

Despite statements on your product labeling marketing your products, “FOR RESEARCH USE ONLY” and “NOT INTENDED FOR HUMAN USE,” evidence obtained from your website establishes that your products are intended to be drugs for human use. Your products are drugs as defined by section 201(g)(1) of the FD&C Act 21 U.S.C. 321(g)(1) because they are intended to prevent, treat, or cure disease conditions and/or affect the structure or function of the body. Examples of claims observed on your website that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following:

“RETA” (Retatrutide)

On your webpage https://www.xcelpeptides.com/product/reta/:

  • “Retatrutide, a triple agonist peptide, interacts with glucagon, GIP, and GLP-1 receptors. In clinical trials, it exhibits potential for weight management by regulating appetite and metabolism in research test subjects.”
  • “Enhanced Insulin Sensitivity . . . By enhancing insulin sensitivity, retatrutide peptide helps test subjects maintain stable blood glucose levels and reduces the risk of developing metabolic disorders associated with insulin resistance.”
  • “Cardiovascular Protection . . . [R]etatrutide peptide has been shown to improve endothelial function, reduce arterial stiffness, and lower blood pressure, thus reducing the risk of cardiovascular diseases such as hypertension and atherosclerosis.”

“CagriLean” (Cagrilintide and Semaglutide)

On your webpage https://www.xcelpeptides.com/product/cagrilean/:

  • “Cagrilintide and semaglutide blend that aids test subjects in managing weight and improving blood sugar levels. This peptide combination helps research subjects feel fuller for longer, curbing their appetite and enhancing metabolic function.”
  • “Understanding Cagrilintide and Semaglutide . . . Cagrilintide is a synthetic peptide known for its ability to regulate appetite. It mimics the natural hormone amylin, which plays a crucial role in controlling hunger and food intake. On the other hand, Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It has been extensively researched for its effects on glucose regulation and appetite suppression.”
  • “Enhanced Glucose Regulation . . . CagriLean helps maintain stable blood glucose levels, reducing the risk of glucose spikes and crashes. This can be instrumental in experiments focusing on insulin sensitivity, glucose metabolism, and the development of diabetes treatments.”

“CAGRILINTIDE”

On your webpage https://www.xcelpeptides.com/product/cagrilintide/:

  • “Enhanced Glucose Control . . . By influencing the release of insulin and other hormones involved in glucose metabolism, it may help stabilize blood sugar levels. This effect could be beneficial for research test subjects with conditions such as diabetes or insulin resistance.”
  • “Improved Lipid Profile: Research suggests that Cagrilintide may also have favorable effects on lipid metabolism, leading to improvements in lipid profiles. By influencing the breakdown and utilization of fats, it may help lower levels of triglycerides and LDL cholesterol while increasing HDL cholesterol levels.”
  • “Cagrilintide exhibits a wide range of potential health benefits for research test subjects, spanning appetite regulation, glucose control, weight management, lipid metabolism, inflammation, cardiometabolic protection, neuroprotection, and the convenience of long-acting formulation.”

“MAZDUTIDE”

On your webpage https://www.xcelpeptides.com/product/mazdutide/:

  • “Mazdutide. . .[is] designed to mimic the actions of a hormone called glucagon-like peptide-1 (GLP-1). It offers numerous benefits in research subjects, such as improving blood sugar control by stimulating insulin secretion and reducing appetite. Additionally, it aids in weight management and may enhance cardiovascular health by lowering blood pressure and improving cholesterol levels.”
  • “Cardiovascular Health: Mazdutide exhibits cardioprotective effects, which could be advantageous for research test subjects at risk of cardiovascular diseases. GLP-1 receptor activation has been linked to improvements in cardiovascular function, such as reducing blood pressure and improving lipid profiles.”

“SEMA” (Semaglutide)

On your webpage https://www.xcelpeptides.com/product/sema/:

  • “Regulation of Blood Sugar Levels: Sema exhibits potent glucose-lowering effects by stimulating insulin secretion and inhibiting glucagon release, two crucial mechanisms in maintaining blood sugar balance.”
  • “Weight Loss and Appetite Suppression: . . . By acting on specific receptors in the brain, this peptide promotes satiety and reduces food intake, leading to decreased body weight and fat mass.”
  • “Neuroprotective Potential: Emerging evidence suggests that semaglutide peptide may possess neuroprotective properties, offering potential benefits in neurodegenerative diseases such as Alzheimer’s disease.”

“SURVODUTIDE”

On your webpage https://www.xcelpeptides.com/product/survodutide/:

  • “Survodutide. . .belongs to a class of drugs known as dual agonists, meaning it targets two different types of receptors in the body: the glucagon receptor and the glucagon-like peptide-1 (GLP-1) receptor. These receptors play crucial roles in regulating various bodily functions, including metabolism, appetite, and blood sugar levels.”
  • “Health Benefits of Survodutide . . . Improved Blood Sugar Control[.] One of the most significant benefits of survodutide is its ability to improve blood sugar control in research lab subjects . . .. [I]t can help regulate blood glucose levels more effectively than targeting either receptor alone. In research subjects, this dual action has shown promise in stabilizing blood sugar levels, which is crucial for managing conditions like diabetes."

“SERMORELIN”

On your webpage https://www.xcelpeptides.com/product/sermorelin/:

  • “Sermorelin, a peptide studied in clinical trials, is believed to enhance the release of growth hormone in subjects. This heightened growth hormone production is associated with potential benefits, including improved metabolism and the facilitation of weight loss.”
  • “Enhanced Muscle Growth and Repair[.] One of the primary benefits observed in test subjects administered with sermorelin is enhanced muscle growth and repair.”
  • “Improved Metabolism and Fat Loss[.] Another notable benefit of sermorelin is its potential to improve metabolism and aid in fat loss.”

Your “RETA” (Retatrutide), “CagriLean” (Cagrilintide and Semaglutide), “CAGRILINTIDE,” “MAZDUTIDE,” “SEMA” (Semaglutide), “SURVODUTIDE,” and “SERMORELIN” products are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).

Conclusion

This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.

This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.

Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will complete the correction.

Your response should be sent to U.S. Food and Drug Administration, CDER/OC/Office of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.

Sincerely,

/S/

Tina Smith, M.S.

Captain, U.S. Public Health Service

Director

Office of Unapproved Drugs and Labeling Compliance

Office of Compliance

Center for Drug Evaluation and Research

Food and Drug Administration

Content current as of:

12/17/2024

Regulated Product(s)

Drugs

Sources

  1. FDA. Warning letter to Xcel Research LLC, December 10, 2024 (MARCS-CMS 694608). fda.gov
  2. FDA. About warning and close-out letters. Content current as of March 20, 2024. fda.gov
  3. FDA. Warning letters: search page and notice on later changes in regulatory status. fda.gov
  4. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. sections 331, 351, 352, 353a, 353b and 355. Office of the Law Revision Counsel. uscode.house.gov

Log every dose in mg with the vial it came from, so there is a record if something goes wrong.

Open Dose Insider